A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma.

Trial Profile

A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs LN 144 (Primary) ; Vemurafenib (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jan 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 22 Jul 2016 Status changed from active, no longer recruiting to discontinued.
    • 17 Nov 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top